Why the study?
Microvascular obstruction (MVO) following reperfusion in STEMI adds incremental risk, including adverse cardiac remodelling, larger infarct size, and worse outcomes, making it a potential therapeutic target.
Microvascular obstruction following primary PCI for STEMI is associated with adverse remodeling and worse outcomes, representing an important therapeutic target.
Answers are grounded in this paper and cite their sources.
May aid post-STEMI risk stratification; leaves open whether targeting microvascular obstruction improves outcomes.
Microvascular obstruction (MVO) is a recognised phenomenon following mechanical reperfusion in patients presenting with ST-segment elevation myocardial infarction (STEMI). Invasive and non-invasive modalities to detect and measure the extent of MVO vary in their accuracy, suggesting that this phenomenon may reflect a spectrum of pathophysiological changes at the level of coronary microcirculation. The importance of detecting MVO lies in the observation that its presence adds incremental risk to patients following STEMI treatment. This increased risk is associated with adverse cardiac remodelling seen on cardiac imaging, increased infarct size, and worse patient outcomes. This review provides an outline of the pathophysiology, clinical implications, and prognosis of MVO in STEMI. It describes historic and novel pharmacological and non-pharmacological therapies to address this phenomenon in conjunction with primary PCI.
No takes yet. Share an insight, caveat, or question.
Ghobrial et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: